Home >> Industry News >> All The News
  • Also available via:

Mido 2009: drop of 9% in visitors PDF
Submit Your News
International News
Monday, 16 March 2009
Visitor attendance figures were better than expected at almost 42,000, falling by just 9% over 2008. Moreover, good signs are coming from the industry. Mido is very pleased with the increase in Italian visitors at + 3%, while the numbers of overseas visitors fell, especially from Asia, by an average 18%.

The exhibition area occupied 10% less space than in 2008 which set a record in the history of Mido at 54,000 square meters. Mido has therefore proved once again to be the most important exhibition for the industry, a forum for opticians and buyers from other countries (54%) and from Italy (46%).

Mido will be held again in Milan on 5-7 March 2010. At the request of all exhibiting companies next years Mido will be reduced to a 3-day event.
Court declines OPSM request of additional damage compensations wrt ex-employee PDF
Submit Your News
Australian News
Monday, 16 March 2009
The Supreme Court of NSW recently declined the compansation claims of OPSM in case of in Luxottica Retail Australia (OPSM) –v– Janet Grant & Ors.

Grant was employed by OPSM as an optometrist. She subsequently accepted employment with Specsavers, a competitor of OPSM. Four days before she resigned she used her manager's computer to send a number of emails and attachments to her home and work computers.

Grant was immediately dismissed the following day after OPSM's National Recruitment manager discovered her actions. OPSM obtained injunctions 2 days later restraining the use of information attached to 4 of the emails sent by Grant.

OPSM relied upon confidentiality clauses in Grant's employment contract, company policies relating to Internet and email usage, and the OPSM's code of conduct.

Although Specsavers and Grant's husband, who also resigned from OPSM to join Specsavers, were named as defendants, there was no evidence that they had acted improperly and no additional final orders were made against them by the Court.

Justice White accepted that Grant sent the emails for personal reasons, including pride in her input in their creation. Nevertheless his Honour confirmed that OPSM had rights with respect to both confidential non-public information and copyright over the attachments.

OPSM's early detection of the soon to be ex-employee's acts and expeditious action in obtaining the injunction restricted damage caused by release of this information. Although only nominal damages were awarded, and the issue of costs is yet to be determined, OPSM maintained and protected its right to property contained in the email attachments.

The principles considered in this case are equally applicable in circumstances where employees misuse computer storage devices such as USB memory sticks or compact discs, to obtain confidential non public information or copyright documents.

In the circumstances of this case, the Court considered the employee's actions were relatively innocent and declined to award additional (deterrence) damages under the Copyright Act. In other circumstances the Court may not be as sympathetic.
Allison signs license agreement for Rock & Republic Eyewear PDF
Submit Your News
Friday, 13 March 2009
Rock & Republic Enterprise and Allison S.p.A. have announced the signing of an exclusive license agreement for the production and distribution of the Rock & Republic sun and vision eyewear collection. The license is for an initial and renewable period of five years.

The sunglass collection will be presented this month and sold in Rock & Republic boutiques and high-end eyewear stores. The vision collection is scheduled for launch January 2010.

Dark, rock and roll, sexy, non-conformist: this is the soul of the exclusive Rock & Republic sunglasses. A fine metal link is the leitmotif of the collection. Shapes are large and wraparound, with materials ranging from metal to acetate, and the glamorous touch of seductive black, white and tortoise colours. Metal colours range from gunmetal gray to black with splashes of gold in some models for women.
Filmmaker plans to install camera in his eye socket PDF
Submit Your News
Feature Story
Friday, 13 March 2009
The Eyeborg Project is the work of Rob Spence, a 36 year old filmmaker residing in Toronto, Canada and Kosta Grammatis, an unemployed engineer from San Francisco, CA. The eye in question was badly damaged in an accident involving a shotgun when Rob was 13. Rob had his eye surgically re moved and replaced with a prosthetic one after enduring ten years of pain. Now, with the help of Kosta and a team of ocularists, inventors, engineering specialists, Rob is building a prosthesis that can capture and transmit video. He will soon be filming the world from an entirely new perspective.

Kosta Grammatis has led the charge to solve the engineering problems involved with the endeavor. In order for the project to be successful the smallest, lightest, power efficient technologies had to be found and implemented. The world's smallest CMOS cameras—1.5mm square are being used, small enough to be lost in a sneeze. The video signal is being transmitted wirelessly to be recorded elsewhere by an RF Transmitter that’s smaller than the tip of a pencil eraser, and lithium polymer battery technology is powering the eye. Kosta envisions that the data will be sent to a backpack to be recorded.

Rob is currently working on a documentary film about the Eyeborg Project and the experience of living with a bionic eye. He hopes it will raise questions and build awareness regarding issues around surveillance in our society.
Bausch & Lomb and Pfizer to Co-Promote Products PDF
Submit Your News
Thursday, 12 March 2009
Bausch & Lomb and Pfizer Inc. announced a co-promotion agreement involving both companies' prescription ophthalmic pharmaceuticals in the United States. The agreement will allow both companies to greatly increase the level of eye care industry support for these important medications that treat serious ophthalmic conditions.

The five-year agreement includes Pfizer’s Xalatan® (latanoprost ophthalmic solution) and Bausch & Lomb’s Alrex® (loteprednol etabonate ophthalmic suspension 0.2%), Lotemax® (loteprednol etabonate ophthalmic suspension 0.5%) and Zylet® (loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension). The co-promotion agreement also will apply to Bausch & Lomb’s investigational anti-infective eye drop, besifloxacin ophthalmic suspension, 0.6%, which is currently awaiting approval from the U.S. Food and Drug Administration (FDA).

Under the terms of the agreement, both the Pfizer and Bausch & Lomb sales forces will promote Xalatan, Alrex, Lotemax, Zylet and besifloxacin (subject to FDA approval).

Separate from this co-promotion agreement with Bausch & Lomb, Pfizer will continue to maintain three mid-stage development programs in its own pipeline.

In December 2008, the FDA's Dermatologic and Ophthalmic Drugs Advisory Committee voted unanimously to recommend approval of besifloxacin for the treatment of bacterial conjunctivitis. Bausch & Lomb anticipates a decision from the FDA in 2009.

Financial terms of the agreement were not disclosed.
<< Start < Prev 221 222 223 224 225 226 227 228 229 230 Next > End >>

Page 226 of 317